CompanySCNINasdaqJerusalem, L3

Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics develops immunology therapies using its NanoAb platform through collaborations with the Max Planck Society and University Medical Center Göttingen.

Stories only

SEC EDGAR ClinicalTrials.gov scinai.com

6-KSep 21Latest SEC filing, period to Sep 21

Sep 8Latest story

September 2026

Scinai ends PC111 arrangements, shifts focus to NanoAb and CDMO business

Sep 8PartnershipScinai Immunotherapeutics Ltd.